Harpoon Presents Interim Data from Ongoing Dose Escalation Portion of T Cell Engager HPN328 Clinical Trial at 2022 ASCO Annual Meeting

SOUTH SAN FRANCISCO, Calif., May 26, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq:HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced interim safety and efficacy data from the ongoing dose escalation and expansion study evaluating HPN328, Harpoon’s half-life extended TriTAC^® targeting delta-like canonical Notch ligand 3 (DLL3), for the treatment of SCLC and other neuroendocrine cancers. The first scientific presentation of these interim data will be featured in a poster session at the American Society of Clinical Oncology (ASCO) Annual Meeting 2022, taking place in Chicago from June 3-7.